# Osteal Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/osteal-therapeutics

- Industry: Biotechnology
- Headquarters: Dallas, US
- Website: www.ostealtx.com/
- Total disclosed funding: $110M
- Latest round: Series D (Jun 5, 2024)
- Investors on record: 7

## About

Founded in 2013 and based in Texas, US, Osteal Therapeutics, Inc. operates as a developer of biopharmaceutical drugs that focuses on developing medicines for the treatment of musculoskeletal infections. Jude Paganelli (CTO) and Brian de Beaubin (CMO) are the co-founders of the company. In June 2024, Osteal Therapeutics, Inc. raised USD 50 million in Series D funding led by Zimmer Biomet Holdings, Inc., including Johnson & Johnson Innovation, Gideon Strategic Partners, and HM Capital. The Series D funding values Osteal Therapeutics, Inc. at USD 231.79 million post-money. As of 2024, the company is led by its CEO, David Thompson.

The company’s primary product, VT-X7, improves outcomes for patients with musculoskeletal infections, including periprosthetic joint infections of the hip and knee. The firm is developing targeted therapies to reduce mortality, morbidity, and healthcare costs associated with these infections. In addition, Osteal is working on the APEX-2 clinical trial, which compares the procedure's performance with two-stage surgery.

The organization plans to use the June 2024 funding to accelerate its development initiatives and commercialization.

## Funding rounds

- Series D, Jun 5, 2024, $50M — Johnson & Johnson Innovation, Biomet, Inc., HM Capital, Gideon Strategic Partners
- Series C, Aug 29, 2023, $22M — Johnson & Johnson Innovation, Medvest Capital, HM Capital, Prism Ventures, Asteroid Partners, Gideon Strategic Partners
- Series B, Dec 29, 2021, $30M — Johnson & Johnson Innovation, Medvest Capital, HM Capital
- Series A, Apr 6, 2018, $7.8M — Johnson & Johnson Innovation, Medvest Capital

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B, Series C, Series D
- Medvest Capital (https://capitalatlas.ai/funds/medvest-capital) — Series A, Series B, Series C
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series B, Series C, Series D
- Prism Ventures (https://capitalatlas.ai/funds/prism-ventures) — Series C
- Asteroid Partners — Series C
- Gideon Strategic Partners (https://capitalatlas.ai/funds/gideon-strategic-partners) — Series C, Series D
- Biomet, Inc. — Series D